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As genetically modified food commodities have entered markets in recent years, domestic
regulators have attempted to manage consumer, environmental and citizen concerns about
these new products. One result has been incomplete and at times inconsistent domestic reg-
ulation, which has created international conflicts about market access. A number of interna-
tional institutions have attempted in recent years to bridge the gulf between exporters and
importers. This paper reviews recent international developments and offers options for dif-
ferent strategies for reducing the current tensions in international markets. 
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I n t r o d u c t i o n
T
he trade policy system is now fully involved in handling disputes about trade in
biotechnologically modified foods. While protests abound against it, production of the
fruits of biotechnology has been increasing sharply. If one looks only at production of
biotechnologically modified crops, James (1999) estimates that global production grew
Vol um e  2   N um be r  1 , 2 00 1/   p. 1 7 8 - 1 8 9 e s t ey j o u r n a l . c o mfrom only a few acres in 1995 to approximately 100 million acres worldwide in 1999. With
increased production comes the search for new markets. At the national level, biotechno-
logically advanced countries have grafted onto their existing regulatory frameworks new
rules and institutions to handle specific concerns about biotechnology. The combination of
incomplete and often conflicting domestic regulatory systems for biotechnologically mod-
ified products and increasing volumes of such products in international commerce has
forced the regulation of products of biotechnology to spill over into the international
sphere. At the international level, several institutions have modified their mandates to give
them entry into the ring of biotechnology regulators. As with the national regulatory sys-
tems, conflicting perspectives about what and how to regulate abound. Suffice it to say that
the current state of affairs at the international level is in a state of flux. While several mech-
anisms attempt to regulate parts of the problem, none provide a comprehensive base for
managing the concerns related to newly crafted biotechnology organisms. 
This piece sets out the parameters of what an international regulatory system must con-
sider, which body or bodies might be best positioned to undertake such regulation, and the
problems that any international attempts at co-ordination are likely to encounter.
A Précis of the International 
Institutions Currently Regulating Biotechnology
T
he biotechnology field is large and diverse and is changing frequently. Innovation and
development have outpaced the development and implementation of an appropriate
regulatory framework, both at the national and international level. There are currently seven
international bodies active in fields affecting the co-ordination and regulation of products
of biotechnology (Buckingham et al., 1999). Table 1 sets out in chronological order of
establishment a summary of the international organisations actively involved in regulating
products of biotechnology.
At the international level, regulatory bodies can be divided between two categories:
those which are science- or health-based, and those with more broadly based objectives like
facilitating international trade, examining environmental considerations, and arbitrating
various other social and/or political goals. The first category includes organisations such as
the International Office of Epizootics (OIE), the Food and Agriculture Organisation’s
International Plant Protection Convention (IPPC), and the joint FAO/World Health
Organisation Codex AlimentariusCommission (Codex). The second category includes such
organisations as the Organisation for Economic Co-operation and Development (OECD),
the World Trade Organisation (WTO), the BioSafety Protocol (BSP), and various regional
initiatives. Each of these institutions’ current activities in the international regulation of
biotechnology are set out in table 1.
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there currently is not any one particular institution appropriately designed to regulate the
vast array of aspects of products of biotechnology.
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Institution Estab. Coverage Member Dispute  Orientation to products
states settlement of biotechnology
International 1924 Pests and pathogens of 155 None;  Creates international
Office of animals and animal standards standards for animal
Epizootics products used by WTO measures involving
quarantines and vaccines
GATT/ WTO 1947/ Trade in all goods and 137 Binding Establishes rules for
1995 most services transparency and dispute
settlement through TBT
and SPS agreements
International 1952 Pests and pathogens of 107 Non-binding; Creates international
Plant plants and plant standards  standards for plant
Protection products used by WTO measures involving
Convention quarantines
OECD 1961 Harmonisation of 29 None Consensus documents for
international regulatory genetic composition of
requirements, standards certain species; policy
and policies development
Codex 1962 Development of food 165 None; Creates international
Alimentarius product composition, standards standards for food,
Commission hygiene requirements used by WTO including composition
and labelling of foods and labelling
Regional 1990s Harmonisation of the Bilateral None Regional side agreements,
initiatives science of regulation MOU, MRA, formal
(TEP; ECTI) dialogues, and joint research
BioSafety 2000 Transboundary 63 signed, None Will require consent from
Protocol (not yet movements of living 0 ratified importing state before
in force) modified organisms (50 required) transboundary movements
(LMOs) of LMOs
Table 1 Current Array of Institutions Regulating International Trade in GM CropsRecent Developments
Four recent developments have re-oriented the discussion of how biotechnology should be
regulated.
First, in November 1999, nine intergovernmental organisations—the World Health
Organisation (WHO), United Nations Conference Trade and Development (UNCTAD),
W TO,  OIE,  FAO,  Convention  on  Biological  Diversity  (CBD),  UN  International
Development Organisation (UNIDO), OECD and the Consultative Group on International
Agricultural Research (CGIAR)—got together for the first comprehensive dialogue on the
international co-ordination of the regulation of biotechnology.1 In May 2000, the group
added the International Centre for Genetic Engineering and Biotechnology (ICGEB) and
the United Nations Development Programme (UNDP) and adopted the name Inter-Agency
Network for Safety in Biotechnology (IANB). This forum for dialogue and clearinghouse
for information on the regulation of biotechnology is a welcome development upon the
international stage.
Second, the riots in the streets of Seattle signalled an end to the private life of the WTO.
Two items are particularly noteworthy about the “Battle for Seattle.” First, the event gal-
vanised civil society protests against multilateral organisations. The trend of “in-your-face”
civil society involvement and protest will require international organisations to rethink how
they operate, how they receive public input, and how they respond to public protest. While
this may make for more transparent and democratic decision making in these institutions,
the involvement of civil society could very likely distract intergovernmental organisations
from their mandates and may drag some of them into areas where their expertise is limited
and where they probably should not go. Civil society is not inclined at present to de-link
analysis into trade issues, finance issues, labour issues, and equity issues, which will make
it difficult to incorporate these areas of concern into the discussions of existing institutions.
Further, Seattle highlighted the failure of member states to articulate and endorse a new
agenda for WTO negotiations. The WTO has found that with 137 members it is hard to
achieve consensus. There is some real fear, given the Seattle failure, that taking on too
much could jeopardise the whole WTO structure. As a result, the WTO is now unlikely to
lead the development of a negotiated solution for the regulation of trade in products of
biotechnology. In response to the Seattle “speed bump” (Horlick, 2000), the WTO has tried
to regroup on issues it can manage. It has begun the “built-in” agricultural negotiations and
made an attempt at harmonising interpretations of the Sanitary and Phyto-sanitary
Measures Agreement (SPS Agreement). Both actions point to a new realism at the WTO. 
Third, the “Cartagena” Protocol on BioSafety was adopted by the Conference of the
Parties to the Convention on Biological Diversity in January 2000 in Montreal. Since the
adoption of the Protocol, 63 nations have signed the text but it will only come into force 90
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when it comes into force, will create a new jurisdictional slice in the pie of international reg-
ulation of biotechnology. Special procedures will have to be followed for international ship-
ments of living modified organisms (LMOs). Specifically, exporters will have to notify
importing countries of any first-time transboundary shipments of LMOs intended for
unconfined release. The importing country then will have the opportunity to undertake a sci-
entifically based assessment of the risks those LMOs pose to the importing country.
Fourth, there have been renewed high-level international talks on biotechnology at the
OECD, between the United States and the EU, and at the G8. Specifically, the OECD dur-
ing 1999/2000 completed a formal review of national and international regulatory structures
and held an international conference on food safety in Edinburgh in March 2000. Since then
the OECD’s work continues to highlight co-ordination, research and standards setting. In
addition to their central role within the OECD, the United States and the European Union
have separately and jointly undertaken new initiatives. Following efforts at domestic renew-
al, on 31 May 2000, the United States and Europe established a bilateral high-level discus-
sion group to look at the risks and benefits of genetically engineered crops and foods
(USDS, 2000). This Consultative Forum concluded in January 2001 with a list of relative-
ly general observations about food safety, health and environmental concerns, the role of
biotechnology in meeting food security needs of developing countries, and market access.
The only recommendation that did not allow much wiggle room was that both countries
should implement mandatory labelling rules.  Now that the forum has reported its findings
to the two governments it is not clear how the governments will respond. Meanwhile, the
G8 Heads of State and Government continue to consider biotechnology and food safety.
Exploring the Options for Regulation
O
ne challenge facing industry and governments is to determine what could be done at
the international level to regulate biotechnology. We believe events over the past year
have, without doubt, redefined the regulatory landscape. Two key conclusions are now
starkly obvious. First, the biotechnology issue is not really one issue at all but a complex
matrix of issues that touch on scientific, political, social, ethical and economic concerns.
Second, it is highly unlikely that any international institution has the scope, the resilience,
the political support, or the expertise to provide and support a comprehensive framework
for the regulation of biotechnology. Both conclusions are perhaps self-evident but they pro-
duce important insights into what types of regulatory structures might or might not work.
Food safety, trade, social, and environmental issues arising from biotechnology require sig-
nificantly different analyses, involve different stakeholders and pose completely different
deal-breaking problems. 
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hensive approach to the regulation of biotechnology next to impossible. Such an approach
is also probably undesirable as comprehensive negotiations often lead to “horse-trading”
that produces anomalies and inconsistencies (Kerr [forthcoming] notes, for example, the
inconsistency of having intellectual property protection within the WTO). Furthermore, it
is not clear whether there is any institution ready to accept such a gargantuan task. The
OECD is facilitating dialogue and collecting data but suffers from a limited membership.
The WTO has its hands full with other trade issues. The BioSafety Protocol has focused on
environmental issues and will be fully occupied in its early years with establishing a frame-
work for balancing international environmental interests without overly distorting interna-
tional trade. Furthermore, consumer concerns and anxiety surrounding GM products cou-
pled with the atmosphere of protest against large organisations demonstrate that compre-
hensive negotiations will be very difficult to sell to consumer and activist groups. 
The alternatives to a comprehensive approach depend on the issues to be addressed.
Public uneasiness about the development and exploitation of biotechnology coalesces
around two basic questions—“is it safe?” and “is it good?” The question “is biotechnology
safe?” leads to a discussion of how we can regulate biotechnology to protect human health
and the environment. Most of the “hard law” of international regulatory agreements that
have been concluded thus far has focused on this first question of whether biotechnology is
safe. The work of the IPPC, the OIE, Codex, and the Consensus Documents of the OECD
all have a primary focus of science-based empirical data to support a conclusion that a
product or a species is safe for human consumption. Risk assessments completed within the
regulatory scope of these bodies also go some way in providing scientific evidence to pro-
tect against more general threats to the environment. The question “is biotechnology
good?” goes beyond matters of science, raising concerns about socio-economic interests
and ethical boundaries for activities. The response to this question raises a whole slate of
subsidiary questions. Should biotechnological inventions be protected and if so how? How
will biotechnology affect the food security of developing countries? How will trade in the
intellectual property and actual products of biotechnology affect competition, market con-
centration and investment opportunities?
These two questions bring into sharp focus the complexity of the regulatory task for
national and international institutions in the area of biotechnology. Without a clear under-
standing of which question it is attempting to address, any institution will likely become
confused, distracted and lose focus. Furthermore, the disciplinary approaches, the tools of
analysis and the methodologies for solutions to the different questions will be different.
Table 2 outlines some of the different dimensions for each question, placing the two major
questions in the context of the methodological approach, disciplines, sources of informa-
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plification of how the different basic questions are analysed, it is designed to establish the
contention that the four major questions cannot be resolved with one approach. The differ-
ent questions require different approaches.
Five specific approaches could be combined to begin to handle the wide array of con-
cerns currently being expressed.
1. Encourage specialised institutions to develop expertise
In many ways, detailed and specialised scientific review has become the norm for the
development of standards for biotechnology products. The OECD Consensus Documents
demonstrate how progress can be made incrementally in the development of a regulatory
scheme for crops. Industry standards (either brands or collective criteria as encompassed
in the systems of the International Standards Organisation [ISO] or Hazard Analysis and
Critical Control Point [HACCP]) can also provide a starting point for international stan-
dards. Standards from Codex, the OIE, and the IPPC could be used to build up a basic,
agreed text of acceptable measures. Bilateral talks between major producer and major con-
sumer nations will then be vital to arrive at a common standard, which could be put for-
ward as an international standard for harmonisation. Harmonisation of risk assessment may
in fact be illusory but the harmonisation of minimum standards and data requirements may
be something that such processes could develop and then feed into the WTO. 
While practical, this “patchwork” approach which defers to specialisation presents cer-
tain problems. Some issues are not immediately taken up by any institution (take for exam-
ple the socio-economic issues). One of the biggest challenges of the current processes is
that there is simply a lack of scientific data upon which to base new standards. Quintillan
(1999), for example, argues that it is unclear how trade rules should respond to scientific
uncertainty about the long-term effects on human health. Perhaps most difficult of all, this
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Health and safety considerations Socio-economic considerations
Scientific method Approach Principles, assumptions, axioms
Natural sciences, mathematics Disciplines Others (social sciences, humanities)
Collect data for proof Information sources Argue from principles to conclusions
From most certain result Conclusion From balancing dialogue, world view
The major questions placed in context
Food Environmental Equity and social Ethical
safety safety concerns concerns
Table 2 A Contextual Mapping of the Issues by Disciplinary Approach approach depends on the negotiating countries having domestic regulations and systems.
These are missing in many importing countries, which would limit this approach to the few
nations with operating regulatory systems.
2. Developing the rules through the case law of the WTO and the IPPC
The processes for handling trade disputes are, for the most part, in place at the WTO.
The benefit of this approach for countries exporting GM crops is that it would not require
further negotiations and it would likely deliver pro-trade, science- and rules-based deci-
sions. However, the case-by-case approach has some very serious drawbacks. Coverage of
issues affecting biotechnology depends on cases actually being brought before the tribunals
in question. The IPPC tribunal has heard no cases. WTO panels have heard cases on health
and food safety issues but are ill equipped to deal with other questions such as how to bal-
ance environmental and socio-economic issues with trade concerns. 
A number of other features, some practical and some systemic, make this approach
problematic. First, there is the long-standing problem of unequal resources between devel-
oped and developing countries to bring a case (or several of them) before the WTO.
Second, depending on the issues that member states would want to take forward to the dis-
pute settlement system, it usually takes years to fully develop a body of law sufficient to
regulate a sphere of activity as complex as trade in GM products. The international com-
munity may not be able to afford to wait that long. Finally, even when decisions are clear
and complete, states do not always comply with the WTO’s binding decisions (e.g., the EU
has not complied with the panel ruling on the beef hormones case). At the end of the day,
a losing party can side-step the consequences of a negative decision by paying compensa-
tion to the successful party. If such compensation is not forthcoming, the successful party
can obtain an authorised suspension of trade benefits towards the losing party and enact
trade sanctions. But in the end, the importing country’s trade is not enhanced. Given the
complexity and strongly held beliefs related to these cases, non-compliance is very possi-
ble, which could undermine the entire WTO system. 
More fundamentally, the case-by-case approach can be attacked in that it is science-
based and there is no institution that can develop a concurrent case law approach to deal
with the outstanding socio-economic issues.
3. An industry-based model of regulation
One possible outcome of slow development of regulations might be for the companies
or parts of the biotechnology industry to implement self-regulation to maintain market
access. There are a number of cases where parts of the agri-food industry have developed
systems to deliver products with higher standards than domestic or even international min-
imum standards. The red meats industry in Australia (Spriggs and Isaac, forthcoming), the
canola industry in Canada (Gray, Malla and Phillips, 1999; Phillips and Smyth, 1999),
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and the corn industry in the United States have all adopted private standards at one time or
another in recent years. Over time, private standards, supplemented by HACCP protocols
or ISO ratings (particularly 9000 and 14000 series) could supplement or replace public reg-
ulation. In order to address market demands, traceability and/or separability, new physical
and organisational infrastructure may be required. Already the International Standards
Organisation has developed new ISO eco-labeling standards (ISO 14020 and ISO 14024)
and has presented industry with the opportunity to use the standards as a way to avoid envi-
ronmental challenges to their products as they are introduced into domestic or foreign mar-
kets (ISO).
This approach is largely undeveloped at present but represents an interesting possibil-
ity for industry to avoid regulation by developing its own standards that will ensure con-
sumer acceptance of their products. A major advantage is that such an approach would not
require industry to bite off large chunks of the regulatory apple. Instead, problems can be
resolved in bite-sized pieces as problems are identified. 
This approach, however, could encounter some obstacles. First, it probably would
depend on a general acceptance of the product, which is not currently present in many mar-
kets. Second, this approach requires collective institutions that are not yet in existence.
These institutions could be commodity groups, trade associations, or new standards under
the umbrella of one of the international standards organisations (Phillips, Henry and Porter,
2000).
4. Issues-based negotiations (bid/offer and MFN) 
Perhaps it is time to go back into the past and adopt an old approach to this new tech-
nology. In the early rounds of GATT negotiations the process was predominantly one of
reciprocal negotiating related to key issues and key markets. A country made bids and
offers with key traders to liberalise specific areas; once bilateral agreements were set, they
were multilateralised through the Most-Favoured-Nation principle. In this way the negoti-
ations focused on those trade issues that had the greatest commercial importance. This
strategy would entail the three countries producing and exporting the bulk of the GM
crops—the United States, Argentina and Canada—engaging in narrowly based negotia-
tions with the key importers—the EU and Japan—related to a handful of GM crops—soy-
beans, corn, cotton and canola. The strong reciprocity of interests in continued interna-
tional trade in those products among those countries would improve the likelihood of suc-
cess. 
The main risks, which are not unique to this approach, are that issues-based negotia-
tions tend to focus on older issues and not on breaking concerns and that trade distortions
and disputes are likely. Furthermore, this approach will isolate many of the recently
mobilised developing nations, which could put pressure on other forums. 
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Currently, the IPPC, OIE and Codex handle health-related international discussions
and the United Nations Environmental Programme handles international environmental
issues, but no single agency (outside of the United Nations itself) has the scope to handle
discussions related to international socio-economic issues. Some have suggested that a new
body or international forum, like the Intergovernmental Panel on Climate Change (IPCC),
is needed to handle the specific issue of the socio-economic implications of biotechnology
(Krebs, 2000; May, 2000). It is unclear, however, what value such an institution would add
to the international community’s efforts to resolve the socio-economic questions. The fun-
damental problem is that while there are many socio-economic issues related to biotech-
nology, many (most) of them are not unique to biotechnology. Questions as to the rights of
development, international and intergenerational equity, indigenous peoples’ or farmers’
rights, the impact of international agreements on farmers and consumers, and even ethical
questions concerning the exploitation of life on the planet are not unique to biotechnology.
Biotechnology may simply be a proxy issue for these larger problems rather than the real
issue to be resolved.
Conclusions and Questions for Further Study
I
t is important to remember that the international regulatory system for biotechnologi-
cally modified products is continually evolving. The activities of the IPPC, the OIE,
Codex, and to a lesser extent the Consensus Documents of the OECD are providing an
elaborate system of scientific data to support the safe development and use of biotechnol-
ogy. That body of scientific knowledge, particularly as it relates to food safety issues, then
feeds into the WTO system through the SPS and TBT (Technical Barriers to Trade) agree-
ments and is credibly able to enlighten panellists who must determine whether measures
are protecting health in the least-trade-distorting way. The problem is that the non-scien-
tific issues have no credible means of being heard and considered. Although some options
exist, more thought is needed on how to handle these other issues. 
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